| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Priority Reports |
1 Integrated Program in Cellular, Molecular, and Biophysical Studies, Departments of 2 Pathology and 3 Medicine, 4 Institute for Cancer Genetics, 5 Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, New York; Departments of 6 Oncology and 7 Pathology, 8 Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund University, Lund, Sweden
Requests for reprints: Ramon Parsons, Institute for Cancer Genetics, 1150 St. Nicholas Avenue, New York, NY 10032. Phone: 212-851-5278; Fax: 212-851-5256; E-mail: rep15{at}columbia.edu.
Deregulation of the phosphatidylinositol 3-kinase (PI3K) pathway either through loss of PTEN or mutation of the catalytic subunit
of PI3K (PIK3CA) occurs frequently in human cancer. We identified PIK3CA mutations in 26% of 342 human breast tumor samples and cell lines at about equal frequency in tumor stages I to IV. To investigate the relationship between PTEN and PIK3CA, we generated a cohort of tumors that had lost PTEN expression and compared it with a matched control set that had retained PTEN. A highly significant association between PIK3CA mutations and retention of PTEN protein expression was observed. In addition, PIK3CA mutations were associated with expression of estrogen and progesterone receptors (ER/PR), lymph node metastasis, and ERBB2 overexpression. The fact that PIK3CA mutations and PTEN loss are nearly mutually exclusive implies that deregulated phosphatidylinositol-3,4,5-triphosphate (PIP3) is critical for tumorigenesis in a significant fraction of breast cancers and that loss of PIP3 homeostasis by abrogation of either PIK3CA or PTEN relieves selective pressure for targeting of the other gene. The correlation of PIK3CA mutation to ER/PR-positive tumors and PTEN loss to ER/PR-negative tumors argues for disparate branches of tumor evolution. Furthermore, the association between ERBB2 overexpression and PIK3CA mutation implies that more than one input activating the PI3K/AKT pathway may be required to overcome intact PTEN. Thus, mutation of PIK3CA is frequent, occurs early in carcinoma development, and has prognostic and therapeutic implications.
Key Words: PTEN PIK3CA PI-3 kinase breast cancer ERBB2
This article has been cited by other articles:
![]() |
P. J.A. Eichhorn, M. Gili, M. Scaltriti, V. Serra, M. Guzman, W. Nijkamp, R. L. Beijersbergen, V. Valero, J. Seoane, R. Bernards, et al. Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235 Cancer Res., November 15, 2008; 68(22): 9221 - 9230. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Oda, J. Okada, L. Timmerman, P. Rodriguez-Viciana, D. Stokoe, K. Shoji, Y. Taketani, H. Kuramoto, Z. A. Knight, K. M. Shokat, et al. PIK3CA Cooperates with Other Phosphatidylinositol 3'-Kinase Pathway Mutations to Effect Oncogenic Transformation Cancer Res., October 1, 2008; 68(19): 8127 - 8136. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ciraolo, M. Iezzi, R. Marone, S. Marengo, C. Curcio, C. Costa, O. Azzolino, C. Gonella, C. Rubinetto, H. Wu, et al. Phosphoinositide 3-Kinase p110{beta} Activity: Key Role in Metabolism and Mammary Gland Cancer but Not Development Sci. Signal., September 9, 2008; 1(36): ra3 - ra3. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wee, D. Wiederschain, S.-M. Maira, A. Loo, C. Miller, R. deBeaumont, F. Stegmeier, Y.-M. Yao, and C. Lengauer PTEN-deficient cancers depend on PIK3CB PNAS, September 2, 2008; 105(35): 13057 - 13062. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Stemke-Hale, A. M. Gonzalez-Angulo, A. Lluch, R. M. Neve, W.-L. Kuo, M. Davies, M. Carey, Z. Hu, Y. Guan, A. Sahin, et al. An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer Cancer Res., August 1, 2008; 68(15): 6084 - 6091. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. E. Velculescu Defining the blueprint of the cancer genome Carcinogenesis, June 1, 2008; 29(6): 1087 - 1091. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-L. Lai, B.-L. Mau, W.-H. Cheng, H.-M. Chen, H.-H. Chiu, and C.-Y. Tzen PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients Ann. Surg. Oncol., April 1, 2008; 15(4): 1064 - 1069. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhao and P. K. Vogt Helical domain and kinase domain mutations in p110{alpha} of phosphatidylinositol 3-kinase induce gain of function by different mechanisms PNAS, February 19, 2008; 105(7): 2652 - 2657. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Abubaker, Z. Jehan, P. Bavi, M. Sultana, S. Al-Harbi, M. Ibrahim, A. Al-Nuaim, M. Ahmed, T. Amin, M. Al-Fehaily, et al. Clinicopathological Analysis of Papillary Thyroid Cancer with PIK3CA Alterations in a Middle Eastern Population J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 611 - 618. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Andre, R. Nahta, R. Conforti, T. Boulet, M. Aziz, L. X. H. Yuan, F. Meslin, M. Spielmann, G. Tomasic, L. Pusztai, et al. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer Ann. Onc., February 1, 2008; 19(2): 315 - 320. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. K. Prasad, M. Tandon, S. Badve, P. W. Snyder, and H. Nakshatri Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover Carcinogenesis, January 1, 2008; 29(1): 25 - 34. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Wasserman and A. R. Tan Evolving Strategies for the Treatment of "Triple-Negative" Breast Cancer ASCO Educational Book, January 1, 2008; 2008(1): 120 - 126. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Huang, D. Mandelker, O. Schmidt-Kittler, Y. Samuels, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, S. B. Gabelli, and L. M. Amzel The Structure of a Human p110{alpha}/p85{alpha} Complex Elucidates the Effects of Oncogenic PI3K{alpha} Mutations Science, December 14, 2007; 318(5857): 1744 - 1748. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Andres-Pons, I. Rodriguez-Escudero, A. Gil, A. Blanco, A. Vega, M. Molina, R. Pulido, and V. J. Cid In vivo Functional Analysis of the Counterbalance of Hyperactive Phosphatidylinositol 3-Kinase p110 Catalytic Oncoproteins by the Tumor Suppressor PTEN Cancer Res., October 15, 2007; 67(20): 9731 - 9739. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Angelo, M. Anita, A. Amalia, and T. Stefania Phosphatidylinositol 3-Kinase in Breast Cancer: Where from Here? Clin. Cancer Res., October 15, 2007; 13(20): 5988 - 5990. [Full Text] [PDF] |
||||
![]() |
M. Barbareschi, F. Buttitta, L. Felicioni, S. Cotrupi, F. Barassi, M. Del Grammastro, A. Ferro, P. Dalla Palma, E. Galligioni, and A. Marchetti Different Prognostic Roles of Mutations in the Helical and Kinase Domains of the PIK3CA Gene in Breast Carcinomas Clin. Cancer Res., October 15, 2007; 13(20): 6064 - 6069. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Ellis and R. Crowder "PIKing" the Winner for Phosphatidylinositol 3-Kinase Inhibitors in ErbB2-Positive Breast Cancer: Let's Not "PTENed" It's Easy! Clin. Cancer Res., October 1, 2007; 13(19): 5661 - 5662. [Full Text] [PDF] |
||||
![]() |
E. Hirsch, C. Costa, and E. Ciraolo Phosphoinositide 3-kinases as a common platform for multi-hormone signaling J. Endocrinol., August 1, 2007; 194(2): 243 - 256. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Miled, Y. Yan, W.-C. Hon, O. Perisic, M. Zvelebil, Y. Inbar, D. Schneidman-Duhovny, H. J. Wolfson, J. M. Backer, and R. L. Williams Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit Science, July 13, 2007; 317(5835): 239 - 242. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Perez-Tenorio, L. Alkhori, B. Olsson, M. A. Waltersson, B. Nordenskjold, L. E. Rutqvist, L. Skoog, and O. Stal PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer Clin. Cancer Res., June 15, 2007; 13(12): 3577 - 3584. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Dimri, M. Naramura, L. Duan, J. Chen, C. Ortega-Cava, G. Chen, R. Goswami, N. Fernandes, Q. Gao, G. P. Dimri, et al. Modeling Breast Cancer-Associated c-Src and EGFR Overexpression in Human MECs: c-Src and EGFR Cooperatively Promote Aberrant Three-dimensional Acinar Structure and Invasive Behavior Cancer Res., May 1, 2007; 67(9): 4164 - 4172. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. H. Saal, P. Johansson, K. Holm, S. K. Gruvberger-Saal, Q.-B. She, M. Maurer, S. Koujak, A. A. Ferrando, P. Malmstrom, L. Memeo, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity PNAS, May 1, 2007; 104(18): 7564 - 7569. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gymnopoulos, M.-A. Elsliger, and P. K. Vogt Rare cancer-specific mutations in PIK3CA show gain of function PNAS, March 27, 2007; 104(13): 5569 - 5574. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Blanco-Aparicio, L. Perez-Gallego, B. Pequeno, J. F.M. Leal, O. Renner, and A. Carnero Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer Carcinogenesis, March 1, 2007; 28(3): 584 - 594. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hollestelle, F. Elstrodt, J. H.A. Nagel, W. W. Kallemeijn, and M. Schutte Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines Mol. Cancer Res., February 1, 2007; 5(2): 195 - 201. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-S. Kim, C. Lee, C. L. Bonifant, H. Ressom, and T. Waldman Activation of p53-Dependent Growth Suppression in Human Cells by Mutations in PTEN or PIK3CA Mol. Cell. Biol., January 15, 2007; 27(2): 662 - 677. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Maruyama, Y. Miyoshi, T. Taguchi, Y. Tamaki, M. Monden, and S. Noguchi Clinicopathologic Analysis of Breast Cancers with PIK3CA Mutations in Japanese Women Clin. Cancer Res., January 15, 2007; 13(2): 408 - 414. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Uddin, A. R. Hussain, A. K. Siraj, P. S. Manogaran, N. A. Al-Jomah, A. Moorji, V. Atizado, F. Al-Dayel, A. Belgaumi, H. El-Solh, et al. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival Blood, December 15, 2006; 108(13): 4178 - 4186. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. L. Gallia, V. Rand, I-M. Siu, C. G. Eberhart, C. D. James, S. K.N. Marie, S. M. Oba-Shinjo, C. G. Carlotti, O. L. Caballero, A. J.G. Simpson, et al. PIK3CA Gene Mutations in Pediatric and Adult Glioblastoma Multiforme Mol. Cancer Res., October 1, 2006; 4(10): 709 - 714. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Watters and C. J. Roberts Developing gene expression signatures of pathway deregulation in tumors. Mol. Cancer Ther., October 1, 2006; 5(10): 2444 - 2449. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Vilgelm, Z. Lian, H. Wang, S. L. Beauparlant, A. Klein-Szanto, L. H. Ellenson, and A. Di Cristofano Akt-Mediated Phosphorylation and Activation of Estrogen Receptor {alpha} Is Required for Endometrial Neoplastic Transformation in Pten+/- Mice. Cancer Res., April 1, 2006; 66(7): 3375 - 3380. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Qiu, F. Schonleben, X. Li, D. J. Ho, L. G. Close, S. Manolidis, B. P. Bennett, and G. H. Su PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., March 1, 2006; 12(5): 1441 - 1446. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Bader, S. Kang, and P. K. Vogt Cancer-specific mutations in PIK3CA are oncogenic in vivo PNAS, January 31, 2006; 103(5): 1475 - 1479. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Oda, D. Stokoe, Y. Taketani, and F. McCormick High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma Cancer Res., December 1, 2005; 65(23): 10669 - 10673. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Isakoff, J. A. Engelman, H. Y. Irie, J. Luo, S. M. Brachmann, R. V. Pearline, L. C. Cantley, and J. S. Brugge Breast Cancer-Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells Cancer Res., December 1, 2005; 65(23): 10992 - 11000. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Frattini, S. Signoroni, S. Pilotti, L. Bertario, S. Benvenuti, C. Zanon, A. Bardelli, and M. A. Pierotti Phosphatase Protein Homologue to Tensin Expression and Phosphatidylinositol-3 Phosphate Kinase Mutations in Colorectal Cancer Cancer Res., December 1, 2005; 65(23): 11227 - 11227. [Full Text] [PDF] |
||||
![]() |
G. Garcia-Rostan, A. M. Costa, I. Pereira-Castro, G. Salvatore, R. Hernandez, M. J.A. Hermsem, A. Herrero, A. Fusco, J. Cameselle-Teijeiro, and M. Santoro Mutation of the PIK3CA Gene in Anaplastic Thyroid Cancer Cancer Res., November 15, 2005; 65(22): 10199 - 10207. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Krop, M. T. Parker, N. Bloushtain-Qimron, D. Porter, R. Gelman, H. Sasaki, M. Maurer, M. B. Terry, R. Parsons, and K. Polyak HIN-1, an Inhibitor of Cell Growth, Invasion, and AKT Activation Cancer Res., November 1, 2005; 65(21): 9659 - 9669. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. G. Campbell, S. E. Russell, W. A. Phillips, D. A. Levine, and J. Boyd PIK3CA Mutations in Ovarian Cancer Clin. Cancer Res., October 1, 2005; 11(19): 7042 - 7043. [Full Text] [PDF] |
||||
![]() |
W. S. El-Deiry Meeting Report: The International Conference on Tumor Progression and Therapeutic Resistance Cancer Res., June 1, 2005; 65(11): 4475 - 4484. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |